GMG

Graphene Manufacturing Group Secures AU$2 Million Funding Grant from Queensland Government for Battery Pilot Plant

Retrieved on: 
Monday, March 25, 2024

BRISBANE, AUS, Mar 25, 2024 - (ACN Newswire) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") announces that the Company has signed a Queensland Critical Minerals and Battery Technology Fund Agreement with the State Government of Queensland for a grant of AU$ 2 million towards the funding of GMG's proposed Automated Battery Pilot Plant for the manufacture of GMG's Graphene Aluminium Ion Battery.

Key Points: 
  • BRISBANE, AUS, Mar 25, 2024 - (ACN Newswire) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") announces that the Company has signed a Queensland Critical Minerals and Battery Technology Fund Agreement with the State Government of Queensland for a grant of AU$ 2 million towards the funding of GMG's proposed Automated Battery Pilot Plant for the manufacture of GMG's Graphene Aluminium Ion Battery.
  • The grant is for the payment of 50% of the capital cost of GMG's proposed Automated Battery Pilot Plant, up to a maximum of AU$ 2 million, for the manufacture of GMG's Graphene Aluminium Ion Battery.
  • The Pilot Plant would be constructed at GMG Richland's existing manufacturing facility, and the grant is conditional on various preconditions including GMG taking a final investment decision in the Battery Pilot Plant project.
  • GMG's CEO Craig Nicol stated, "We want to thank the Queensland Government and acknowledge its commitment to supporting the Critical Mineral and Battery Manufacturing Industry in the State.

Schneider Electric launches Materialize program for Scope 3 decarbonization of natural resources

Retrieved on: 
Wednesday, April 3, 2024

Materialize is a continuation of Schneider Electric’s suite of supply chain decarbonization programs from its Sustainability Business consulting division, which leverage the power of supply chain cohorts for renewable energy procurement at scale.

Key Points: 
  • Materialize is a continuation of Schneider Electric’s suite of supply chain decarbonization programs from its Sustainability Business consulting division, which leverage the power of supply chain cohorts for renewable energy procurement at scale.
  • “We are delighted to launch Materialize as our latest collaborative program to reduce Scope 3 emissions.
  • Both were created to engage thousands of suppliers simultaneously to drive swift and measurable action to reduce program sponsors’ Scope 3 emissions.
  • The portfolio builds on Schneider’s foundational initiative, The Zero Carbon Project , that provides resources and guidance to program participants, encouraging ambitious decarbonization goals with a deployment action plan to achieve it.

NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US

Retrieved on: 
Friday, March 22, 2024

The Phase 2b clinical trial is a dose range-finding, double-blind, placebo-controlled study of NMD670, a twice daily oral muscle-targeted therapy, in gMG patients experiencing persistent symptoms or fluctuating symptoms despite treatment on current standard of care.

Key Points: 
  • The Phase 2b clinical trial is a dose range-finding, double-blind, placebo-controlled study of NMD670, a twice daily oral muscle-targeted therapy, in gMG patients experiencing persistent symptoms or fluctuating symptoms despite treatment on current standard of care.
  • The trial will take place in both US and European clinical sites.
  • Thomas Holm Pedersen, Chief Executive Officer of NMD Pharma, said: “This is an important milestone for NMD Pharma, enabling us to progress our lead development candidate NMD670 into a Phase 2b trial in the US in generalized myasthenia gravis patients with AChR and MuSK positive antibodies.
  • It follows positive Phase 1/2a data which provided proof-of-mechanism and where clinically and statistically significant effects were seen in patients.

NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US

Retrieved on: 
Friday, March 22, 2024

The Phase 2b clinical trial is a dose range-finding, double-blind, placebo-controlled study of NMD670, a twice daily oral muscle-targeted therapy, in gMG patients experiencing persistent symptoms or fluctuating symptoms despite treatment on current standard of care.

Key Points: 
  • The Phase 2b clinical trial is a dose range-finding, double-blind, placebo-controlled study of NMD670, a twice daily oral muscle-targeted therapy, in gMG patients experiencing persistent symptoms or fluctuating symptoms despite treatment on current standard of care.
  • The trial will take place in both US and European clinical sites.
  • Thomas Holm Pedersen, Chief Executive Officer of NMD Pharma, said: “This is an important milestone for NMD Pharma, enabling us to progress our lead development candidate NMD670 into a Phase 2b trial in the US in generalized myasthenia gravis patients with AChR and MuSK positive antibodies.
  • It follows positive Phase 1/2a data which provided proof-of-mechanism and where clinically and statistically significant effects were seen in patients.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results

Retrieved on: 
Thursday, March 21, 2024

NEW YORK and WALTHAM, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023, and provided an update on recent business achievements.

Key Points: 
  • DNTH103 has the potential to be a best-in-class pipeline-in-a-product across a range of autoimmune disorders with high unmet need.
  • Initial top-line results from this trial are anticipated to be available in the second half of 2025.
  • Dianthus successfully completed a private investment in public equity (“PIPE”) financing in January 2024 that resulted in gross proceeds of approximately $230 million.
  • Additional Information – For additional information on the Company’s financial results for the year ended December 31, 2023, please refer to the Form 10-K filed with the SEC.

The MeridianBet - Golden Matrix Transaction Secures Approval at GMGI Shareholder Assembly

Retrieved on: 
Wednesday, March 20, 2024

LAS VEGAS, NV, March 20, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Golden Matrix Group Inc. (NASDAQ:GMGI) (“GMGI”, “Golden Matrix” or the “Company”), a developer, licensor and global operator of online gaming and eCommerce platforms, systems and gaming content, today announced that its stockholders have voted to approve the terms of, and the issuance of shares of common stock in connection with, that certain previously announced Amended and Restated Sale and Purchase Agreement of Share Capital dated June 27, 2023 (as amended and restated from time to time, the “Purchase Agreement”) by and between the Company, as purchaser and Aleksandar Milovanović, Zoran Milošević and Snežana Božović, owners of MeridianBet Group, pursuant to which the Company seeks to acquire MeridianBet Group, at a special meeting.

Key Points: 
  • Commenting on the merger Zoran Milosevic, Chief Executive Officer of MeridianBet Group, said:
    "Today marks a major milestone for MeridianBet and I am thrilled that the shareholders of Golden Matrix have overwhelmingly voted in favor of the acquisition of MeridianBet.
  • By joining forces, we are not only expanding our reach but enhancing our ability to provide customers with a diverse and comprehensive offering whilst creating a leading global betting group.
  • The final voting results for each proposal voted on at the special meeting is set forth in a Current Report on Form 8-K filed by Golden Matrix with the U.S. Securities and Exchange Commission.
  • A full copy of the announcement can be viewed by visiting: https://www.nasdaq.com/articles/golden-matrix-stockholders-vote-to-acqui...

IASO Bio Announces U.S. FDA Approval of Investigational New Drug Application for BCMA CAR-T Equecabtagene Autoleucel for Generalized Myasthenia Gravis

Retrieved on: 
Thursday, April 4, 2024

The Chinese IND for this indication of Equecabtagene Autoleucel was approved by the NMPA in January this year.

Key Points: 
  • The Chinese IND for this indication of Equecabtagene Autoleucel was approved by the NMPA in January this year.
  • The 2 subjects were treated with a single infusion of Eque-cel at the doses of 1.0×106 CAR-T/Kg, respectively.
  • No immunomodulatory therapy other than low dose pyridostigmine (90 mg/day and 60 mg/day, respectively) was used during the follow-up period.
  • Anti-AChR antibodies, anti-Titin antibodies, and anti-MuSK antibodies decreased rapidly and maintained at very low levels in both subjects after infusion.

Harbour BioMed Reports Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024

We recorded a significant increase in our revenue, demonstrating the Company's excellent global business development capabilities," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.

Key Points: 
  • We recorded a significant increase in our revenue, demonstrating the Company's excellent global business development capabilities," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.
  • Harbour BioMed recorded the profit of US$22.8 million for the year ended 31 December 2023.
  • This is the first time that the Company has recorded a net profit on its annual financial statements.
  • Looking to the future, Harbour BioMed will keep driving business growth and accomplishing its mission through two key pillars, Harbour Therapeutics and Nona Biosciences.

Graphene Manufacturing Group Ltd. Commences Trading on OTCQX Under the Symbol GMGMF

Retrieved on: 
Monday, February 26, 2024

Vancouver, BC, Feb 26, 2024 - (ACN Newswire) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce it begins trading today on the OTCQX(R) market under the symbol "GMGMF".

Key Points: 
  • Vancouver, BC, Feb 26, 2024 - (ACN Newswire) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce it begins trading today on the OTCQX(R) market under the symbol "GMGMF".
  • To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/8082/199208_b72d0c1064e979c2_001fu...
    The OTCQX Best Market is for established, investor-focused U.S. and international companies.
  • GMG has now qualified to trade on the OTCQX Best Market, having been upgraded from the Pink(R) market.
  • The two lower-tier markets for OTC trading in the U.S. are the OTCQB Venture Market and the OTC Pink market.

Graphene Manufacturing Group ISO 9001:2015 Certification, Demonstrating Commitment to Quality Management

Retrieved on: 
Tuesday, February 20, 2024

This achievement underscores GMG's commitment to providing its customers with the highest quality products and services, while continuously improving its internal processes.

Key Points: 
  • This achievement underscores GMG's commitment to providing its customers with the highest quality products and services, while continuously improving its internal processes.
  • The ISO 9001 certification process involved a rigorous assessment of GMG's quality management system, covering all aspects of its operations, from customer service to production, delivery, and technical support.
  • The benefits of ISO 9001 certification for GMG include:
    - Enhanced customer satisfaction through improved product and service quality.
  • GMG is committed to maintaining its ISO 9001 certification and continuously improving its quality management system.